Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598273 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
A Phase 3 study, sponsored by Affymax.
- Completed
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
NCT00598273 is a Phase 3 study that has completed, run by Affymax. The registered enrollment target is 490 participants.
The verdict
NCT00598273, a Phase 3 study, has completed, sponsored by Affymax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA) treatment.
Interventions
- DRUG Darbepoetin alfa
- DRUG peginesatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598273
The ClinicalTrials.gov registry entry for NCT00598273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affymax, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Darbepoetin alfa is the first listed.
NCT00598273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598273 about?
NCT00598273 is a clinical study titled "Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis". The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA) treatment.
What is the current status of trial NCT00598273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2007-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00598273?
The interventions under investigation include: Darbepoetin alfa (DRUG), peginesatide (DRUG).
Who is sponsoring clinical trial NCT00598273?
This trial is sponsored by Affymax, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.